Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
CBIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Crescent Biopharma, Inc.NASDAQ: CBIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $23.28M (cash outflow) rose 893.4% year over year, ahead of the +206.1% change in trailing-twelve-month net income. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +47.5% a year.
Context
- Net income amounted to 1382.7% of revenue in FY2025.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$35.26M (-76.5%) for the fiscal year ending Dec 2026, a slowdown from the +295.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.28M-74.8% QoQ
- Last fiscal yearDec 2025
- -$149.94M+295.8% YoY
- LTMMar 2026
- -$162.08M+206.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (149.94M) USD
- Year-over-year change
- -295.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (149.94M) | -295.8% |
| FY2024 | 2024-12-31 | (37.88M) | -2.7% |
| FY2023 | 2023-12-31 | (36.9M) | +21.0% |
| FY2022 | 2022-12-31 | (46.69M) | +26.4% |
| FY2021 | 2021-12-31 | (63.43M) | — |
Net Income vs competitors
How CBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +206.1% is the highest of 9, against a peer median of +31.9%.
- Net income amounts to 1363.9% of revenue for CBIO, versus a peer median of 107.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $460M USD | +54.4% | +9.8% | 393.2% | |
| LTM Sep 2026 | $309.06M USD | +37.6% | +32.1% | 275948.2% | |
| LTM Mar 2026 | $162.08M USD | +206.1% | +47.5% | 1363.9% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥150.96M CNY | -47.8% | -67.2% | — |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M USD | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $59.14M USD | -242.2% | -44.1% | 166.4% | |
| LTM Sep 2026 | $43.31M USD | +168.3% | — | 16.3% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Dec 2025 | $35.34M USD | — | — | 48.6% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CBIO) | — | +31.9% | +9.8% | 107.5% | |
Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.43M) | (46.69M) | (36.9M) | (37.88M) | (149.94M) |
| Depreciation & Amortization | 264.6K | 207.15K | 153.3K | 35.17K | 84K |
| Deferred Income Tax | 2.17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.09M | 3.86M | 3.56M | 4.77M | 13.3M |
| Change in Working Capital | (1.17M) | (4.66M) | (2.56M) | 1.16M | (13.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (18M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 17.68K | (1.14M) | (102.08K) | (538.81K) | 2.08M |
| Other Working Capital | (1.18M) | (3.52M) | (2.46M) | 1.7M | 2.55M |
| Other Non-Cash Items | 749.04K | 828.51K | 864.87K | 814.48K | 78.4M |
| Operating Cash Flow | (57.49M) | (46.46M) | (34.88M) | (31.1M) | (71.53M) |
| Capital Expenditures | (14.94K) | (84.19K) | (21.39K) | (9.97K) | (919K) |
| Acquisitions (Net) | 0 | 0 | 0 | 30K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (72M) |
| Investing Cash Flow | (14.94K) | (84.19K) | (21.39K) | 20.03K | (72.92M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 10.7M | 4.16M | 28.71M | 5.4K | 5K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (177K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 25.03K | 0 | 116.5K | 0 | 323.16M |
| Financing Cash Flow | 10.72M | 4.16M | 28.82M | 5.4K | 322.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.78M) | (42.38M) | (6.08M) | (31.07M) | 178.53M |
| Free Cash Flow | (57.5M) | (46.54M) | (34.9M) | (31.11M) | (72.45M) |
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.